Lupus Nephritis Care Pathway
Evaluation of a Lupus Nephritis Care Pathway Integrating Telemedicine and Clinical Pharmacist Practitioners
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Procedures mentioned: Questionnaires, Interviews
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Activities include answering surveys and participating in an interview."
- "The study primarily assesses the LN Care Pathway's feasibility and acceptability using surveys, exit interviews, and metrics of enrollment, retention, and engagement."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study tests a care plan for about 25 people with lupus nephritis, or kidney inflammation caused by lupus. It looks at how well the plan works for patients and whether it may help them take medicines as directed and improve their health. Patients will answer surveys and take part in an interview.
The purpose of this study is to evaluate an approach to managing patients with lupus nephritis called the Lupus Nephritis (LN) Pathway among approximately 25 patients. Activities include answering surveys and participating in an interview. Objectives include: 1) Assess feasibility and acceptability of the LN Care Pathway, 2) evaluate user experiences to identify opportunities for improvement, and 3) explore the preliminary effect of this pathway on medication adherence and clinical outcomes.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Currently get care at a Duke University Health System clinic.
- Have systemic lupus erythematosus (SLE), a disease where the immune system attacks the body, diagnosed using accepted medical standards.
- Are age 18 or older.
- Can understand the study and agree to take part.
- Can attend medical visits by phone or video.
- Have new or ongoing active kidney inflammation from lupus, as judged by a lupus or kidney doctor.
Who can't join
- Have severe problems with thinking or understanding.
- Do not want to keep getting care at Duke University Health System over time.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Active patient at a Duke University Health System clinic * Current diagnosis of Systemic Lupus Erythematosus (SLE) based on the 1997 ACR,32 2012 Systemic Lupus International Collaborating Clinics (SLICC),33 or 2019 European League Against Rheumatism (EULAR)/ACR (American College of Rheumatology)34 classification criteria * Aged 18 years or older * Able to provide informed consent * Able to attend telemedicine visits * New onset or ongoing active LN based on rheumatologist or nephrologist evaluation Exclusion Criteria: * Patients with severe cognitive impairment * Do not wish to receive longitudinal care at our health system
Study sites (1)
NC
- Duke University · Durham, NC 27708Kai Sun, MD · Study contactDana Burshell, MPH · Study contactKai Sun, MD · Principal investigatorLisa Criscione-Schreiber, MD · Sub-investigatorMore trials in Durham